Cadrenal Therapeutics Inc —— 季度财务数据 (NASDAQ:CVKD)

Financials

经营活动产生的现金 -1.79 M-4.65 M-3.03 M-2.36 M-2.57 M -12.6 M 投资活动产生的现金 -6 537-3 2510-1 8530 -5 104 融资活动产生的现金 7.45 M1.97 M1.26 M648.36 K2.72 M 6.6 M 自由现金流 -1.8 M-4.65 M-3.03 M-2.36 M-2.57 M -12.61 M

新闻

Cadrenal schedules FDA meeting for HIT drug CAD-1005

Cadrenal Therapeutics股价因二期临床试验结果大涨

Cadrenal Therapeutics stock surges on Phase 2 trial results

Cadrenal的CAD-1005在HIT试验中显示血栓减少

Cadrenal’s CAD-1005 shows reduction in blood clots in HIT trial

Cadrenal强调12-LOX抑制剂对血液疾病的潜力

Cadrenal highlights potential of 12-LOX inhibitor for blood disorder

Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox

Cadrenal Therapeutics appoints PTC Therapeutics CMO to board

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics首席财务官Szot出售价值1496美元股票